Inactive Instrument

Cesca Therapeutics Inc Stock Nasdaq

US1571311034

Valuation: Cesca Therapeutics Inc

Market Cap	11.09K 9.7K 8.95K 8.27K 15.68K 1.06M 15.95K 107K 41.99K 521K 41.65K 40.74K 1.79M	P/E 2022	-0.16x	P/E 2023	-0.08x
Enterprise Value	9.29M 8.13M 7.5M 6.92M 13.14M 886M 13.36M 89.58M 35.18M 437M 34.89M 34.13M 1.5B	EV / Sales 2022	0.97x	EV / Sales 2023	1.18x
Free-Float	100%	Yield 2022 *	-	Yield 2023	-

* Estimated data More valuation ratios

Latest news : Cesca Therapeutics Inc

24-07-16	ThermoGenesis Holdings, Inc. Announces Resignation of Jeffery Cauble as Chief Financial Officer	CI
24-07-11	ThermoGenesis Holdings, Inc. Receives A Notice of Default from Boyalife Group, Inc	CI
24-06-26	ThermoGenesis Holdings, Inc. Announces Board and Committee Resignations	CI
24-06-19	ThermoGenesis Holdings, Inc.(NasdaqCM:THMO) dropped from S&P TMI Index	CI
24-06-13	ThermoGenesis Holdings, Inc.(OTCPK:THMO) dropped from NASDAQ Composite Index	CI
24-06-12	Wall Street Set to Open Higher Wednesday as Key Inflation Data Lower Than Expected	MT
24-06-12	US Futures Slightly Higher Ahead of Fed's Rate Decision, Key Inflation Data	MT
24-06-12	Top Premarket Decliners	MT
24-06-04	ThermoGenesis Corp. Enters into A Manufacture and Supply Agreement with CBR Systems, Inc	CI
24-05-17	ThermoGenesis Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-16	ThermoGenesis Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-04-15	ThermoGenesis Holdings, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-03-12	Thermogenesis Holdings, Inc. Announces Resignation of Haihong Zhu, Chief Operating Officer and A Director from the Board	CI

More news

Analysts' recommendations: Cesca Therapeutics Inc

22-08-12	HC Wainwright Adjusts ThermoGenesis Holdings' Price Target to $1 from $6, Keeps Buy Rating	MT
20-11-13	THERMOGENESIS : HC Wainwright Adjusts ThermoGenesis Holdings' Price Target to $8.50 From $9.50, Keeps at Buy	MT

More recommendations

Press Releases: Cesca Therapeutics Inc

24-07-11	ThermoGenesis : Accelaration/Increase of Financial Obligation Form 8 K	PU
24-03-20	ThermoGenesis : Material Event - Form 8-K	PU
23-11-13	ThermoGenesis Holdings Announces Third Quarter 2023 Financial Results and Provides Corporate Update	PR
23-11-08	ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide a Corporate Strategic Update	PR
23-10-26	ThermoGenesis to Open a New 35,500 Square Foot ReadyStart-IncuStart cGMP Facility in Greater Sacramento	PR

More press releases

Managers and Directors: Cesca Therapeutics Inc

Manager	Title	Age	Since
Xiao Chun Xu CEO	Chief Executive Officer	55	2016-11-02
Wendy Samford IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Xiao Chun Xu CHM	Chairman	55	2016-11-02
Biao Xi BRD	Director/Board Member	-	2023-07-13

More insiders

Scientific & Precision Equipment

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CESCA THERAPEUTICS INC	-4.15%	-9.96%	-	-	1.58K
METTLER-TOLEDO INTERNATIONAL, INC.	+0.63%	-0.94%	+4.85%	+0.20%	26.19B
SHIMADZU CORPORATION	+3.50%	-0.07%	+21.19%	-5.37%	7.41B
MLOPTIC CORP.	+1.95%	+6.93%	+129.36%	+228.11%	4.74B
TECAN GROUP AG	+4.51%	+3.39%	+9.39%	-46.21%	2.84B
SVG TECH GROUP CO.,LTD.	-1.66%	-1.84%	+204.16%	+162.63%	2.47B
JEOL LTD.	+7.73%	+3.85%	+83.20%	+63.87%	2.37B
NINGBO YONGXIN OPTICS CO.,LTD	-1.91%	-4.92%	+40.90%	+34.25%	1.98B
PARK SYSTEMS CORP.	-6.59%	+3.65%	-12.21%	+55.15%	1.25B
BASLER AG	+0.52%	+3.96%	+139.64%	+75.15%	1.02B
Average	+0.45%	+2.27%	+68.94%	+63.09%	5.59B
Weighted average by Cap.	+1.34%	+0.63%	+36.47%	+33.47%

See all sector performances

ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.

Employees

Sector

Office Equipment

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

	2022	2023
Net sales	10.48M 9.17M 8.46M 7.81M 14.82M 1B 15.07M 101M 39.68M 493M 39.36M 38.5M 1.69B	9.44M 8.26M 7.62M 7.04M 13.35M 901M 13.58M 91.05M 35.75M 444M 35.46M 34.69M 1.53B
Net income	-11.27M -9.86M -9.09M -8.4M -15.93M -1.07B -16.2M -109M -42.66M -530M -42.32M -41.39M -1.82B	-17.98M -15.72M -14.5M -13.39M -25.42M -1.71B -25.84M -173M -68.05M -845M -67.49M -66.02M -2.9B
Net Debt	6.89M 6.02M 5.56M 5.13M 9.74M 657M 9.9M 66.4M 26.08M 324M 25.86M 25.3M 1.11B	9.28M 8.12M 7.49M 6.92M 13.12M 885M 13.34M 89.48M 35.14M 436M 34.85M 34.09M 1.5B

Cesca Therapeutics Inc Stock Nasdaq

Stocks